The ATMP Service Providers market size was accounted at USD 13.85 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 10.9% from 2022 to 2030. Advanced Therapy Medicinal Products (ATMPs) are therapies for human consumption with an active therapeutic substance that may be based on the technology to modify a patient's genome, recombinant nucleic acids or genes, engineered tissue and substantially manipulated cells or cells intended for a different essential function in the patient versus the donor. They offer groundbreaking new opportunities to treat life-threatening diseases where one or limited doses have a curative effect. In the case of gene-based ATMPs, recombinant genes are generated in the lab by combining several DNA from different sources to treat genetic abnormalities, cancer, or long-term diseases. In cell-based therapies, cells are modified to change their biological properties or cells or tissues that are not meant for the same vital roles in the body. They are capable of curing, diagnosing, and preventing diseases. Tissue-engineered therapies of ATMP have cells or tissues that have been modified to be used to repair, regenerate or replace human tissue. ATMP services include analysis of active therapeutic substances, documentation, standards and regulations in GMP, and logistics like storage and transportation.
Increasing demand for personalized medication pushes the technology towards advancements in biological therapeutics, leading to innovative Advanced Therapy Medicinal Products, which is the crucial factor for ATMP service providers' market growth. Extensive research activities, rising approvals for new drug products, stakeholders' investments in clinical trials and Large pipeline products will boost the service providers' market. The COVID-19 outbreak has adversely affected the overall medical industry, but the pandemic enabled the operations and development of advanced therapeutics. In Feb 2022, Takara Bio, Inc expanded the GMP facility to accommodate a variety of modalities and strengthen the supply chain. The facility's expansion, which went into operation in 2020, increased production capacity.
Lack of production capabilities and cost of services regarding ATMP production are significant factors affecting the progress of the ATMP services providers market. The availability of a significant number of FDA-approved advanced therapy medicinal products in the United States has gained a substantial share of revenue in the North America region.
Global ATMP Service Providers market is segmented into by type services and by applications. Type of services comprises analytics, quality, CMO, logistics. The subsegment analytics covers Microbiology, Endotoxin, PCR, Flow Cytometry, ELISA, Container Closure, Sterilty, and Pre-clinical. Quality subegment has documentation, QMS and regulations. Whereas, CMO includes HQ/GMP plasmid DNA, MSC manufacture, Pluripotent stem cells. In logistics, storage, stability and transport are subdivisions. CMO will contribute the largest share of the revenue in the coming years in the ATMP service providers market. Secondly, the segmentation by application contains GTMP(Gene Therapy Medicinal Products), sCTMP(somatic Cells Therapy Medicinal Products) and TEP(Tissue Engineered Products).
Significant market players are Takara Bio, NorthX Biologics, Cellco Labs, AWA, ClinStorage, Key2Complience, Nordic BioAnalysis, YSDS, Truly Labs, ABC Labs, Mikrolabs, NDA group, Propharma group, Celonic, Bio Elpida, CGT Catapult, Rentschler Biopharma SE, AGC Biologics, Catalent, WuXi Advanced Therapies, BlueReg, Minaris Regenerative Medicine, Patheon, Bio-Techne Corporation, bioMérieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A., Sistemic Scotland Limited, Thermo Fisher Scientific Inc., Vigene Biosciences, Inc., WuXi AppTec and others.